SCHEMBL3426528

SCHEMBL3426528

CCC1OC1CC1OC1CC1OC1CC1OC1CC1OC1CC1OC1CCC(C)=O

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.30
SLC15A2 Q16348 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13409098 0.85 PAOX (0.38) ALDH1A1
SCHEMBL28332885 0.82 ALDH1A1 (0.36) ALDH1A1LMNASLC15A2
SCHEMBL17653600 0.78 CES1 (0.37) ALDH1A1
SCHEMBL7994854 0.77 FFAR3 (0.40) ALDH1A1LMNA
SCHEMBL12176250 0.75
SCHEMBL12672981 0.74 ALDH1A1 (0.33) ALDH1A1
SCHEMBL3746246 0.74 GPR84 (0.44) ALDH1A1LMNA
SCHEMBL835135 0.74 CES2 (0.41) ALDH1A1
Ethylene Glycol SCHEMBL28276062 0.72 FFAR3 (0.36) ALDH1A1
SCHEMBL3108530 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163800-B2 PKC-activating compounds for the treatment of neurodegenerative diseases BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) 2012-04-24 US disclosed
US-20120027687-A1 FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE WEST VIRGINIA UNIVERSITY 2012-02-02 US disclosed
US-20100022645-A1 PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022645-A1 PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases PRKCH, PRKCA, PRKCG ALDH1A1 3269/4885LMNA 1513/4885SLC15A2 4162/4885
US-20120027687-A1 FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE PRKCA, FABP7, PRKCZ ALDH1A1 3610/4885LMNA 450/4885SLC15A2 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.